论文部分内容阅读
目的观察凌氏验方对老年肺癌患者免疫功能的调节作用。方法 30例Ⅲ-Ⅳ期老年非小细胞肺癌患者,予凌氏验方治疗2个月,观察患者血清T细胞亚群(CD3+、CD4+、CD4+/CD8+、NK细胞)及免疫抑制因子(TGFβ-1)水平变化及中医证候变化。结果凌氏验方可以提高晚期老年非小细胞肺癌患者血清T细胞亚群(CD3+、CD4+/CD8+、NK细胞)水平,同时显著降低免疫抑制因子(TGFβ-1)水平,临床收益率(有效+稳定)为76.67%。结论凌氏验方具有多靶点改善老年肺癌免疫功能的作用。
Objective To observe the regulatory effect of Lingshi prescription on immune function in elderly patients with lung cancer. Methods Thirty patients with stage Ⅲ-Ⅳ elder non-small cell lung cancer were treated with Lingshi prescription for 2 months. The levels of T lymphocyte subsets (CD3 +, CD4 +, CD4 + / CD8 +, NK cells) and immunosuppressive factors ) Level changes and TCM syndrome changes. Results Ling’s prescription can increase the level of serum T cell subsets (CD3 +, CD4 + / CD8 +, NK cells) in patients with advanced non-small cell lung cancer and significantly decrease the level of TGF-β1, and the clinical rate of return ) Is 76.67%. Conclusion Lingshi Prescription has multiple targets to improve immune function in elderly patients with lung cancer.